Nighttime Dosing

nighttime dosing

Daytime Coverage

daytime coverage

Parkinson's disease patient with dyskinesia walking with grandchildren at a gardening store Parkinson's disease patient with dyskinesia walking with grandchildren at a gardening store
GOCOVRI® is the only medication indicated for both dyskinesia and OFF episodes in Parkinson's disease (PD) patients taking levodopa.1

For Parkinson's disease patients with motor complications,1,2

Gocovri® could mean the difference

between getting up and getting out

GOCOVRI® is ready when your Parkinson’s disease (PD) patients with dyskinesia or OFF episodes need it.

With a single nighttime dose, high levels of GOCOVRI® are reached by morning before the first levodopa dose, providing all-day coverage with levels slowly decreasing in the hours before bedtime.2

See how Gocovri® can help
Not an actual patient.
Watch the full episode, originally aired on Lifetime Television®

Explore a day in the life of Lee, a PD patient, and his care partner, Chari, and see how they manage Lee’s motor complications.

Hear from board-certified neurologist and movement disorder specialist Dr. Salima Brillman, as she talks about the highs and lows experienced by people with Parkinson’s, and the “balancing-act” of treating OFF episodes and dyskinesia.

Dyskinesia Movement, Icon
Reductions in Motor Complications2

GOCOVRI® is proven to decrease dyskinesia (primary endpoint) while also reducing OFF time and increasing ON time without troublesome dyskinesia (secondary endpoints)

see the data
GOCOVRI® Prescription Form, Icon
GOCOVRI® Prescription Form

Prescribe GOCOVRI® and register patients for GOCOVRI Onboard® with 1 form

download now
Patient Access, Icon
Patient Access

See how GOCOVRI Onboard® can help your patients with dyskinesia or OFF episodes access GOCOVRI®

LEARN MORE

INDICATION and important safety information

GOCOVRI® (amantadine) extended release capsules is indicated:

  • For the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications
  • As adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing “off” episodes

It is not known if GOCOVRI is safe and effective in children.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS
GOCOVRI is contraindicated in patients with creatinine clearance below 15 mL/min/1.73 m2.

WARNINGS AND PRECAUTIONS

Falling Asleep During Activities of Daily Living and Somnolence: Patients treated with Parkinson’s disease medications have reported falling asleep during activities of daily living. If a patient develops daytime sleepiness during activities that require full attention (e.g., driving a motor vehicle, conversations, eating), GOCOVRI should ordinarily be discontinued or the patient should be advised to avoid potentially dangerous activities.

Suicidality and Depression: Monitor patients for depression, including suicidal ideation or behavior. Prescribers should consider whether the benefits outweigh the risks of treatment with GOCOVRI in patients with a history of suicidality or depression.

Hallucinations/Psychotic Behavior: Patients with a major psychotic disorder should ordinarily not be treated with GOCOVRI because of the risk of exacerbating psychosis. Observe patients for the occurrence of hallucinations throughout treatment, especially at initiation and after dose increases.

Dizziness and Orthostatic Hypotension: Monitor patients for dizziness and orthostatic hypotension, especially after starting GOCOVRI or increasing the dose.

Withdrawal-Emergent Hyperpyrexia and Confusion: Rapid dose reduction or abrupt discontinuation of GOCOVRI, may cause an increase in the symptoms of Parkinson’s disease or cause delirium, agitation, delusions, hallucinations, paranoid reaction, stupor, anxiety, depression, or slurred speech. Avoid sudden discontinuation of GOCOVRI.

Impulse Control/Compulsive Behaviors: Patients may experience urges (e.g. gambling, sexual, money spending, binge eating) and the inability to control them. It is important for prescribers to ask patients or their caregivers about the development of new or increased urges. Consider dose reduction or stopping medications.

ADVERSE REACTIONS
The most common adverse reactions (>10%) were hallucination, dizziness, dry mouth, peripheral edema, constipation, fall, and orthostatic hypotension.

View the full Prescribing Information.

References:
  1. GOCOVRI® (amantadine) [Prescribing Information]. Emeryville, CA. Adamas Pharma LLC; 2021.
  2. Hauser RA, Pahwa R, Wargin WA, et al. Pharmacokinetics of ADS-5102 (amantadine) extended release capsules administered once daily at bedtime for the treatment of dyskinesia. Clin Pharmacokinet. 2018;58(1):77-88.